Cisplatin News and Research

RSS

New therapies for acute kidney injury show promise

Acute kidney injury (AKI) is a severe renal disorder affecting approximately 10%-15% of hospitalized patients and up to 50% in intensive care units (ICUs). Its pathogenesis involves complex inflammatory regulatory mechanisms. As core components of the cytokine network, interleukins (ILs) exert pleiotropic effects in AKI development, extensively participating in inflammation, fibrosis, tissue injury repair, and remote organ damage.

18 Aug 2025

Diagnostic mimicry and management of rare pure form of ovarian cancer

A new case report was published in Volume 12 of Oncoscience on July 28, 2025, titled "A rare case of pure non-gestational ovarian choriocarcinoma: Diagnostic mimicry and management strategies."

14 Aug 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025

Deep learning model predicts adverse drug reactions from chemical structure

Adverse drug reactions (ADRs) are a significant cause of hospital admissions and treatment discontinuation worldwide. Conventional approaches often fail to detect rare or delayed effects of medicinal products.

7 Aug 2025

Starfish compound overcomes drug resistance in prostate cancer models

Researchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate cancer cells in vitro by bypassing common resistance pathways. CuC1 showed synergy with existing chemotherapies, though with only moderate selectivity for cancer cells.

5 Aug 2025

CPADS enables comprehensive analysis of drug resistance across 44 cancer types

CPADS integrates data from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and the Genomics of Drug Sensitivity in Cancer (GDSC) databases, encompassing over 29,000 samples across 44 cancer types and involving 288 drugs. It provides five main analysis modules: differential expression analysis, correlation analysis, pathway analysis, drug analysis, and gene perturbation analysis.

30 Jul 2025

Restoring mitochondria enhances immune response against lung cancer

While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for long-term control.

28 Jul 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

Combination therapy sets new survival standard for advanced biliary tract cancer

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis.

10 Jul 2025

Scientists reveal how chemotherapy causes genetic damage in healthy blood

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

2 Jul 2025

Advancing treatment for urothelial cancer with enfortumab vedotin and pembrolizumab

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy."

2 Jul 2025

Targeting mitochondrial dynamics to combat breast cancer metastasis

Breast cancer, particularly triple-negative breast cancer (TNBC), remains a leading cause of cancer-related mortality due to its aggressive nature and limited therapeutic targets.

27 Jun 2025

Study finds overlap between chemotherapy side effects and brain aging

While chemotherapy can be lifesaving, it also damages DNA and leads to cognitive issues known as "chemo brain." These effects resemble the memory and learning problems seen in older adults, prompting University of Oklahoma researchers to investigate this unique overlap of cognitive decline.

26 Jun 2025

New DNA test predicts chemotherapy resistance in cancer patients

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a test which can successfully predict whether cancer will resist common forms of chemotherapy treatment.

23 Jun 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

Unmasking Nrf2 as a key driver of treatment resistance in osteosarcoma

A deeper understanding of osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, is reshaping strategies for overcoming treatment resistance.

20 Apr 2025

Enfortumab vedotin and pembrolizumab show major benefits for urothelial carcinoma patients

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, urothelial carcinomas grow in the bladder (bladder carcinoma).

4 Apr 2025

Adding chemotherapy to radiotherapy does not improve outcomes for cervical cancer patients

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma indicated that the addition of chemotherapy did not improve outcomes for patients and led to increased toxicity for patients.

14 Mar 2025

First-ever clinical trials evaluate fenofibrate as treatment for HPV-related cancers

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC).

28 Feb 2025

New ASTRO guideline offers radiation therapy recommendations for anal cancer

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma (SCC) of the anal canal and anal margin.

27 Feb 2025